Search research articles
Contact Us
Filters
Showing results (741-750 of 784) with videos related to
Page
of 79
Sort By:
Gut
|
October 26, 2021
Duodenal <i>Anaerobutyricum soehngenii</i> infusion stimulates GLP-1 production, ameliorates glycaemic control and beneficially shapes the duodenal transcriptome in metabolic syndrome subjects: a randomised double-blind placebo-controlled cross-over study
Annefleur Koopen, Julia Witjes, Koen Wortelboer, et al.
Nature Communications
|
August 20, 2016
Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus
Pierre Martinez, Margriet R Timmer, Chiu T Lau, et al.
Inflammatory Bowel Diseases
|
December 31, 2015
Dietary Patterns and Risk of Inflammatory Bowel Disease in Europe: Results from the EPIC Study
Antoine Racine, Franck Carbonnel, Simon S M Chan, et al.
Gastrointestinal Endoscopy
|
March 15, 2022
Analysis of metastases rates during follow-up after endoscopic resection of early "high-risk" esophageal adenocarcinoma
Esther A Nieuwenhuis, Sanne N van Munster, Sybren L Meijer, et al.
Nucleic Acids Research
|
November 17, 2007
ORegAnno: an open-access community-driven resource for regulatory annotation
Obi L Griffith, Stephen B Montgomery, Bridget Bernier, et al.
Nature Cell Biology
|
September 7, 2021
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer
Alastair Davies, Shaghayegh Nouruzi, Dwaipayan Ganguli, et al.
Endoscopy
|
June 1, 2021
Incidence and outcomes of poor healing and poor squamous regeneration after radiofrequency ablation therapy for early Barrett's neoplasia
Sanne N van Munster, Charlotte N Frederiks, Esther A Nieuwenhuis, et al.
Trials
|
November 5, 2021
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
Bastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
European Urology Oncology
|
October 1, 2025
Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis
Karan Parekh, Kim van der Zande, Sarah W S Ng, et al.
European Urology Oncology
|
July 12, 2025
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer
Sandra van Wilpe, Tarek Taha, Emily C Rothmann, et al.
Page
of 79
Search research articles
Search
Showing results (741-750 of 784) with videos related to
Sort By:
Page
of 79
Gut
|
October 26, 2021
Duodenal <i>Anaerobutyricum soehngenii</i> infusion stimulates GLP-1 production, ameliorates glycaemic control and beneficially shapes the duodenal transcriptome in metabolic syndrome subjects: a randomised double-blind placebo-controlled cross-over study
Annefleur Koopen, Julia Witjes, Koen Wortelboer, et al.
Nature Communications
|
August 20, 2016
Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus
Pierre Martinez, Margriet R Timmer, Chiu T Lau, et al.
Inflammatory Bowel Diseases
|
December 31, 2015
Dietary Patterns and Risk of Inflammatory Bowel Disease in Europe: Results from the EPIC Study
Antoine Racine, Franck Carbonnel, Simon S M Chan, et al.
Gastrointestinal Endoscopy
|
March 15, 2022
Analysis of metastases rates during follow-up after endoscopic resection of early "high-risk" esophageal adenocarcinoma
Esther A Nieuwenhuis, Sanne N van Munster, Sybren L Meijer, et al.
Nucleic Acids Research
|
November 17, 2007
ORegAnno: an open-access community-driven resource for regulatory annotation
Obi L Griffith, Stephen B Montgomery, Bridget Bernier, et al.
Nature Cell Biology
|
September 7, 2021
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer
Alastair Davies, Shaghayegh Nouruzi, Dwaipayan Ganguli, et al.
Endoscopy
|
June 1, 2021
Incidence and outcomes of poor healing and poor squamous regeneration after radiofrequency ablation therapy for early Barrett's neoplasia
Sanne N van Munster, Charlotte N Frederiks, Esther A Nieuwenhuis, et al.
Trials
|
November 5, 2021
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
Bastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
European Urology Oncology
|
October 1, 2025
Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis
Karan Parekh, Kim van der Zande, Sarah W S Ng, et al.
European Urology Oncology
|
July 12, 2025
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer
Sandra van Wilpe, Tarek Taha, Emily C Rothmann, et al.
Page
of 79